Glen Tullman has ‘no interest’ in selling Transcarent

The latest stories trending on MedCity News.

Editor's Pick

Top Story Glen Tullman Has 'No Interest' In Selling Transcarent, But IPO Is a Possibility Transcarent recently announced that it raised $126 million in Series D funding led by General Catalyst and 7wireVentures. When asked what his exit strategy is, CEO Glen Tullman said he does not want to sell Transcarent, but sees an initial public offering as an option. Sponsored Content Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience Presented by Care Logistics This eBook, details how hospitals and health systems can facilitate more effective decision making via elevated awareness. With the right tools in place, organizations can expedite strategic achievement across every area of the system. Register for INVEST 2024, May 21-22 in Chicago! INVEST 2024 is a healthcare investment conference that unites startups, investors, and industry leaders to forge new connections and delve into emerging trends transforming the healthcare sector.   Secure your attendance at this premier boutique conference offering unparalleled networking opportunities for healthcare professionals and investors.   Don't Let Time Slip Away - Register Now!

Featured News

Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression.

Resources

Debunked| No-Fluff Healthcare News Show | Presented by MedCity News | Episode 4 In this episode we discuss abortion and how the Arizona's House and Senate voted to repeal the 1864 law that nearly banned all abortions after this recording. When this repeal goes into effect, abortions in the state will be banned only after 15 weeks. We also delve into the recent data exchange debate between Epic and Particle and so much more. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe